Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.
Acute promyelocytic leukemia (APL) is distinguished from other acute myeloid leukemias (AMLs) by cytogenetic, clinical, as well as biological characteristics. The hallmark of APL is the t(15;17), which leads to the expression of the PML/RARalpha fusion protein. PML/RARalpha is the central leukemia-inducing lesion in APL and is directly targeted by all trans retinoic acid (t-RA) as well as by arsenic, both compounds able to induce complete remissions. This review focuses on potential stem cell involvement in APL outlining the knowledge about the APL-initiating stem cell and the influence of PML/RARalpha on the biology of the hematopoietic stem cell. Moreover, the importance of the blockage of t-RA signaling by the PML/RARalpha for the pathogenesis of APL is discussed, taking the relevance of the t-RA signaling pathway for the global hematopoiesis into account.
Puccetti
E
E
Med. Klinik III/Abtl. Hämatologie, Labor für Experimentelle Hämatologie, Johann Wolfgang Goethe-Universität, Frankfurt, Germany.
Ruthardt
M
M
D017209:Apoptosis; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D009363:Neoplasm Proteins / Q000502:physiology*; D014411:Neoplastic Stem Cells / Q000502:physiology*; D015514:Oncogene Proteins, Fusion / Q000502:physiology*; D015398:Signal Transduction; D014212:Tretinoin / Q000494:pharmacology
D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin